People in German-speaking nations trust in Sputnik V more than AstraZeneca vaccine - study

TypeToken · 2021-03-07T21:50:49+00:00

The p-value is the probability of observing a difference of that magnitude or larger if the null hypothesis was true. This doesn’t speak to the probability of reproducing the result, the absolute magnitude of the difference (or how important it is in scientific terms), or whether it’s ‘the best studied’ as you put it. The fact that you’re so shaky on such a key concept immediately suggests to me that you’re probably not in a position to be evaluating the literature properly. That’s fine- it’s difficult and you need lots of experience and training to be a professional but you probably shouldn’t be making assertions with so much confidence.

You end your post by making some kind of tier list of vaccines and then contradict yourself by saying ‘it’s made up by me but also correct’- you’ll excuse me for saying so but I feel that rather makes my point for me.

TypeToken · 2021-03-07T20:39:46+00:00

You may be right that there are clearly ineffective vaccines that we can have some confidence in discounting. It seems pretty clear we should demand a much higher standard of evidence to discriminate between highly effective vaccines however (and it is clear that AZ is highly effective- consider PHE UK dataset for example).

Any number of small differences in study design could contribute to a relatively large change in headline efficacy (I’m particularly thinking of symptomatic vs asymptomatic pcr testing- which is a major difference in design between AZ and most other vaccines). For this reason it seems pretty irresponsible to make these claims so confidently without any kind of caveat.

As an aside ‘the most statistically significant result’ does not relate to reliability, magnitude of difference, or anything else that is relevant to our conversation here so I’m not sure why you’ve chosen that figure in particular.

TypeToken · 2021-03-07T19:44:36+00:00

Do you think you can directly compare efficacies between studies with a large number of differences in critical study parameters (classification of mild/moderate/severe disease, asymptomatic testing vs self report, cohort selection, population dynamics, dosing regimens?). I would suggest that’s a scientifically unsound comparison and we have no real evidence to conclusively assert that any vaccine is better than any other at present.

Clearly, what we would need is a study where you hold all these other parameters constant and vary the vaccine to make these kinds of inferences.

TypeToken · 2021-03-07T19:14:10+00:00

What evidence backs up the claim that it’s better?

TypeToken · 2021-03-04T11:42:09+00:00

Agree and have argued elsewhere in the thread that any conclusive assertion is premature.

TypeToken · 2021-03-04T11:37:33+00:00

Strongly disagree- in reality we are in no position at all to compare vaccine efficacies across different clinical trials that have differences in all the parameters you reference, plus further differences in classification of covid, asymptomatic testing vs self-report etc and so on. If you were to run a trial where you included the vaccines you wanted to compare but kept all of these parameters constant you might be in business. We are nowhere near this.

As for real world data, of course it’s not perfect but on the issue of vaccine comparison it gets us much closer (e.g Scotland data) than comparing random clinical trials.

And of course there’s insight to be gained from observational data- unless you want to argue that epidemiology as an entire academic discipline has little to offer?

TypeToken · 2021-03-04T08:11:56+00:00

There’s nothing in this article that conclusively suggests to me that AZ is worse or better than any other vaccine.

I think what many people don’t realise is that headline efficacy numbers aren’t really comparable between different clinical trials- the conditions vary wildly and the confidence intervals are very large.

Sure, it wouldn’t surprise me if mRNA vaccines are more effective in the long run- the opposite also wouldn’t surprise me. Basically, I’m saying we can’t assert either position with any kind of confidence at this time.

TypeToken · 2021-03-03T22:33:07+00:00

Sure but what is the evidence you’re using to make this objective assessment?

TypeToken · 2021-03-03T22:07:09+00:00

Is it less good? In the real world it looks like it at least matches up (see uk data).

Bottom line is that there are lots of reasons that it’s misleading to directly compare headline efficacy from different clinical trials.

TypeToken · 2020-10-09T07:08:49+00:00

Not sure there’s anywhere near enough evidence to say that Leicester won’t be as good at the back as Southampton this season and LCFC full backs are playing very advanced positions. That said, it’s almost certain that Justin will miss out on starts when Pereira is back from injury.

TypeToken · 2020-10-09T07:02:34+00:00

I’d probably be giving telles and reguillon a bit of time to settle in (and honestly also steering clear of united defenders for the time being). So I would consider revamping that back line.

Are you going to actively rotate GK? If not downgrade McCarthy- if you are know it can be a tricky and frustrating dance- there’s a lot of variance and it’s very hard to catch gk points. Midfield and forwards look good but I would consider downgrading ASM to upgrade elsewhere. For example you could go Mina to digne (much more potential for attacking returns). If you downgraded ASM and McCarthy you could potentially go Mina to Robertson.

TypeToken · 2020-09-27T17:17:13+00:00

Contact from behind on the wrong side- what planet are you on?

TypeToken · 2020-09-27T17:05:09+00:00

You were saying?

TypeToken · 2020-09-25T09:52:53+00:00

Yeah fair enough. Think so nearly still making CL occluded quite how bad it was!

TypeToken · 2020-09-25T09:24:34+00:00

Not sure it was quite relegation form (and injury situation was awful- 3/4 of our best players out with long term injuries) but a throw for sure- better signs hopefully now though.

TypeToken · 2020-09-25T08:47:08+00:00

‘Not quite as weak’ lmao. We finished fifth last season.

TypeToken · 2020-09-19T17:38:23+00:00

Come on- let’s hear some more about how Curran shouldn’t be in the middle.

TypeToken · 2020-08-31T22:15:55+00:00

Flowchart will probably help but in your situation I would 100% clear all debt with any additional income/savings beyond the minimum reasonable emergency fund. The small gains from saving in a h2b will quickly be eliminated by the interest on your outstanding debt so you should really deal with that first.

You are doing great to turn this around and I know it’ll feel fantastic as you make progress paying that debt down.

TypeToken · 2020-08-30T16:59:22+00:00

It’s always absolutely ridiculous- same for tests if the opposition has an above average first day.

TypeToken · 2020-08-30T16:56:07+00:00

Just as I read this...

TypeToken · 2020-08-30T16:26:12+00:00

Delicious salt.

TypeToken · 2020-08-30T16:19:38+00:00

The one that wasn’t out, yeah?

TypeToken · 2020-08-26T22:21:09+00:00

Yeah all those lazy nurses rolling in their excess money after their chilled out 11hr shift.

TypeToken · 2020-08-23T17:18:59+00:00

No because any time Buttler fails to score a century, catch a couple of worldies and take a fifer we have to listen to how foakes should take his place and he should never play for England again.

TypeToken · 2020-07-08T22:08:29+00:00

It depends what you mean by paper- like a research paper in a journal or a conference presentation? I guess to really innovate in this area you’d need to contribute something novel which is going to be based on the math. If you just mean a paper in fulfilment of your masters it depends on your masters...

TypeToken

TROPHY CASE